Hi everyone, this is KalaGhazi and today I will be talking about Reata that just rocketed 200% yesterday.
Reata Pharmaceuticals RETA stock skyrocketed almost 200% on Wednesday, a day after the FDA approved its drug Skyclarys, or omaveloxolone, across a broad patient population of an ultra-rare disease called Friedreich’s ataxia.
Shares of Reata have surged 200.3% in the past year against the industry’s 9.9% decline.
Reata’s new rare-disease drug will cost $370,000 per year.
Who on earth has the money for this treatment???
Reata Pharmaceuticals RETA stock skyrocketed almost 200% on Wednesday, a day after the FDA approved its drug Skyclarys, or omaveloxolone, across a broad patient population of an ultra-rare disease called Friedreich’s ataxia.
Shares of Reata have surged 200.3% in the past year against the industry’s 9.9% decline.
Reata’s new rare-disease drug will cost $370,000 per year.
Who on earth has the money for this treatment???